Search for ""

NO results found.

latest entries

C3a-Receptor monoclonal antibodies from University of Goettingen
C3a are known to trigger mast cell degranulation (Anaphylatoxin)
Means and Methods for Treating Peripheral and Cardiovascular Diseases via Modulation of Arteriogenesis offered by Max-Planck-Innovation
Trpv4 is highly suitable for the development of new therapeutic concepts in order to cure peripheral and cardiovascular diseases
Genentech is interested in a broad range of therapeutic candidates and enabling technologies
Merck Serono is interested in oncology, neurodegenerative, autoimmune, inflammatory, fertility and endocrinology opportunities
New Antimalarials offered by AWSG, Vienna
A new bridged compound shows significant activity against a multiresistant strain of Plasmodium falciparum and against Plasmodium berghei in a mouse model

© 2006-2007
by Herbert-Worch-Foundation